Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Lancet Oncol · 2011 · PMC3159416 · PMID 21641867

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Neither trial showed a significant reduction in survival with intermittent therapy, although OPTIMOX-2 showed a trend in favour of continuation of fluorouracil during oxaliplatin breaks, and has been adopted as the benchmark for standard practice.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.